Format

Send to

Choose Destination
Neurobiol Aging. 2015 Mar;36(3):1600.e1-4. doi: 10.1016/j.neurobiolaging.2014.12.023. Epub 2014 Dec 24.

Blood methylomic signatures of presymptomatic dementia in elderly subjects with type 2 diabetes mellitus.

Author information

1
Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon, UK. Electronic address: k.lunnon@exeter.ac.uk.
2
MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College, London, London, UK.
3
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel.
4
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel; Department of Neurology, Sheba Medical Center, Ramat Gan, Israel.
5
Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon, UK; MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College, London, London, UK.
6
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel; Department of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: michal.beeri@mssm.edu.

Abstract

Due to an aging population, the incidence of dementia is steadily rising. The ability to identify early markers in blood, which appear before the onset of clinical symptoms is of considerable interest to allow early intervention, particularly in "high risk" groups such as those with type 2 diabetes. Here, we present a longitudinal study of genome-wide DNA methylation in whole blood from 18 elderly individuals with type 2 diabetes who developed presymptomatic dementia within an 18-month period following baseline assessment and 18 age-, sex-, and education-matched controls who maintained normal cognitive function. We identified a significant overlap in methylomic differences between groups at baseline and follow-up, with 8 CpG sites being consistently differentially methylated above our nominal significance threshold before symptoms at baseline and at 18 months follow up, after a diagnosis of presymptomatic dementia. Finally, we report a significant overlap between DNA methylation differences identified in converters, only after they develop symptoms of dementia, with differences at the same loci in blood samples from patients with clinically diagnosed Alzheimer's disease compared with unaffected control subjects.

KEYWORDS:

Alzheimer's disease (AD); Biomarker; Blood; DNA methylation; Dementia; Epigenetics; Type 2 diabetes

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center